SB 1848 In Committee
Controlled Substances - As enacted, authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without the use of naloxone; adds that prescribing a buprenorphine product to nursing mother or prescribing an injectable mono product does not restrict certain healthcare providers from prescribing a buprenorphine product for the treatment of opioid use disorder without naloxone. - Amends TCA Title 53, Chapter 11.
Introduced
In Committee
Floor
Crossed Over
Passed
Enacted
Apr 24, 2026 · House
Comp. became Pub. Ch. 753
Mar 30, 2026 · House
Companion House Bill substituted
Mar 27, 2026 · House
Placed on Senate Regular Calendar for 3/30/2026
Mar 18, 2026 · House
Recommended for passage, refer to Senate Calendar Committee
Mar 17, 2026 · House
Placed on Senate Health and Welfare Committee calendar for 3/18/2026
Mar 17, 2026 · House
Action deferred in Senate Health and Welfare Committee to 3/18/2026
Mar 11, 2026 · House
Placed on Senate Health and Welfare Committee calendar for 3/17/2026
Mar 11, 2026 · House
Action deferred in Senate Health and Welfare Committee to 3/18/2026
Mar 4, 2026 · House
Placed on Senate Health and Welfare Committee calendar for 3/11/2026
Feb 18, 2026 · House
Action deferred in Senate Health and Welfare Committee to 3/4/2026
Feb 11, 2026 · House
Placed on Senate Health and Welfare Committee calendar for 2/18/2026
Feb 2, 2026 · Senate
Passed on Second Consideration, refer to Senate Health and Welfare Committee
Jan 22, 2026 · House
Introduced, Passed on First Consideration
Jan 21, 2026 · House
Filed for introduction